MedTrace Logo

Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma

NCT05752877 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-03-03

No results posted yet for this study

Summary

The goal of this clinical trial is to estimate the safety, tolerance and initial efficacy of target IL-13Rα2 or B7-H3 UCAR-T cell injection in the treatment of patients with advanced glioma, as well as the pharmacokinetic characteristics of its metabolites after single and multiple administrations and the biomarkers related to efficacy, safety and drug metabolism.

Conditions

  • Advanced Glioma
  • Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy

Interventions

BIOLOGICAL

Targeted IL-13 Rα2 UCAR-T cell injection

local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.

BIOLOGICAL

Targeted B7-H3 UCAR-T cell injection

local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.

Sponsors & Collaborators

  • Soochow T-Maximun Biotechnology Co. LTD

    collaborator UNKNOWN

  • Second Affiliated Hospital of Soochow University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05752877 on ClinicalTrials.gov